Research programme: glucocorticoid receptor modulators - Ligand
Alternative Names: LGD 5552Latest Information Update: 06 Jul 2010
Price :
$50 *
At a glance
- Originator Ligand Pharmaceuticals
- Class Small molecules
- Mechanism of Action Glucocorticoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Mar 2007 Ligand Pharmaceuticals discontinues development of LGD 5552, but will continue to develop other potential drug candidates
- 01 Jul 2005 Data presented at the 87th Annual Meeting of the Endocrine Society (ENDO-2005) have been added to the Inflammatory disorders pharmacodynamics section
- 28 Jun 2004 Data presented at the 86th Annual Meeting of the Endocrine Society (ENS-2004) have been added to the Neurological disorders pharmacodynamics section